ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Pittsburgh, PA, USA:

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Pittsburgh, Pennsylvania, United States and 59 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 211 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Pittsburgh, Pennsylvania, United States and 126 other locations

of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Monroeville, Pennsylvania, United States and 21 other locations

and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Alnuctamab
Drug: Iberdomide

Phase 1

Juno Therapeutics

Pittsburgh, Pennsylvania, United States and 18 other locations

Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. W...

Enrolling
Relapsed and Refractory Multiple Myeloma
Drug: Ixazomib
Drug: Dexamethasone

Phase 1, Phase 2

Kathleen Dorritie

Pittsburgh, Pennsylvania, United States

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

Phase 3

AbbVie
AbbVie

Pittsburgh, Pennsylvania, United States and 180 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 135 other locations

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 26 other locations

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Carfilzomib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 30 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems